title: Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.
abstract: This retrospective, interventional case series analyses treatment outcomes in eyes with choroidal neovascularization (CNV) secondary to pathological myopia, managed with photodynamic therapy, (PDT), (Group 1, N = 11), PDT and intravitreal triamcinolone acetonide (4 mg/0.1ml) (Group 2, N = 3), PDT and intravitreal anti-vascular endothelial growth factor (anti-VEGF) bevacizumab 1.25 mg/0.05 ml, ranibizumab 0.5 mg/0.05 ml and reduced-fluence PDT and intravitreal ranibizumab 0.5 mg/0.05 ml (Group 3, N=12). All the patients underwent PDT. Intravitreal injections were repeated as required. SPSS 14 software was used to evaluate the data. Wilcoxon signed ranks test was used to evaluate pre- and post-treatment vision. The Kruskal-Wallis test was used for comparison between the groups. All the groups were statistically comparable. All the eyes showed complete regression of CNV, with a minimum follow-up of six months. All groups had visual improvement; significantly in Group 3 ( p = 0.003). Combination PDT with anti-VEGF agents appeared to be efficacious in eyes with myopic CNV. However, a larger study with a longer follow-up is required to validate these results.
authors.affiliation: Shri Bhagwan Mahavir Vitreo Retinal Services, Sankara Nethralaya, 18 College Road, Chennai - 600 006, Tamil Nadu, India. docrishi@yahoo.co.in
authors.forename: Pukhraj
authors.initials: P
authors.lastname: Rishi
authors.forename: Ekta
authors.initials: E
authors.lastname: Rishi
authors.forename: Anusha
authors.initials: A
authors.lastname: Venkataraman
authors.forename: Lingam
authors.initials: L
authors.lastname: Gopal
authors.forename: Tarun
authors.initials: T
authors.lastname: Sharma
authors.forename: Muna
authors.initials: M
authors.lastname: Bhende
authors.forename: Dhanashree
authors.initials: D
authors.lastname: Ratra
authors.forename: Pratik Ranjan
authors.initials: PR
authors.lastname: Sen
authors.forename: Parveen
authors.initials: P
authors.lastname: Sen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D006801:Humans; D058449:Intravitreal Injections; D047728:Myopia, Degenerative / Q000150:complications*; D010778:Photochemotherapy; D000069579:Ranibizumab; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide; D000069579:Ranibizumab